Loading...

Santen Pharmaceutical

OTCPK:SNPH.F
Snowflake Description

Flawless balance sheet average dividend payer.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
SNPH.F
OTCPK
¥683B
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Santen Pharmaceutical Co., Ltd. researches and develops, produces, and markets pharmaceuticals and medical devices in Japan and internationally. The last earnings update was 46 days ago. More info.


Add to Portfolio Compare Print
SNPH.F Share Price and Events
7 Day Returns
0%
OTCPK:SNPH.F
2.6%
US Pharmaceuticals
2%
US Market
1 Year Returns
-16.3%
OTCPK:SNPH.F
10%
US Pharmaceuticals
4.3%
US Market
SNPH.F Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Santen Pharmaceutical (SNPH.F) 0% 0% - -16.3% 3.8% -71.5%
US Pharmaceuticals 2.6% 2.4% 0% 10% 13.5% 16.5%
US Market 2% 4.1% 4.2% 4.3% 43.9% 40.8%
1 Year Return vs Industry and Market
  • SNPH.F underperformed the Pharmaceuticals industry which returned 10% over the past year.
  • SNPH.F underperformed the Market in United States of America which returned 4.3% over the past year.
Price Volatility
SNPH.F
Industry
5yr Volatility vs Market
Related Companies

Sorry, no analysis for Santen Pharmaceutical's competitors could be found in our database.

Value

 Is Santen Pharmaceutical undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Santen Pharmaceutical to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Santen Pharmaceutical.

OTCPK:SNPH.F Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 10 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 7.5%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for OTCPK:SNPH.F
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.64
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.643 (1 + (1- 30.86%) (0%))
0.761
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.8
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (0.8 * 5.96%)
7.5%

Discounted Cash Flow Calculation for OTCPK:SNPH.F using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Santen Pharmaceutical is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

OTCPK:SNPH.F DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (JPY, Millions) Source Present Value
Discounted (@ 7.5%)
2019 27,149.00 Analyst x3 25,255.35
2020 25,163.25 Analyst x4 21,775.39
2021 32,845.71 Analyst x7 26,440.98
2022 36,105.67 Analyst x6 27,037.95
2023 44,043.75 Analyst x4 30,681.91
2024 42,593.33 Analyst x3 27,601.92
2025 41,945.95 Est @ -1.52% 25,286.42
2026 41,843.20 Est @ -0.24% 23,465.07
2027 42,114.15 Est @ 0.65% 21,969.72
2028 42,649.96 Est @ 1.27% 20,697.35
Present value of next 10 years cash flows ¥250,212.07
OTCPK:SNPH.F DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= ¥42,649.96 × (1 + 2.73%) ÷ (7.5% – 2.73%)
¥918,924.06
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= ¥918,924.06 ÷ (1 + 7.5%)10
¥445,939.33
OTCPK:SNPH.F Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= ¥250,212.07 + ¥445,939.33
¥696,151.40
Equity Value per Share
(JPY)
= Total value / Shares Outstanding
= ¥696,151.40 / 399.16
¥1744.03
OTCPK:SNPH.F Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in OTCPK:SNPH.F represents 0.00886x of TSE:4536
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.00886x
Value per Share
(Listing Adjusted, USD)
= Value per Share (JPY) x Listing Adjustment Factor
= ¥ 1,744.03 x 0.00886
$15.45
Value per share (USD) From above. $15.45
Current discount Discount to share price of $15.15
= -1 x ($15.15 - $15.45) / $15.45
2%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Santen Pharmaceutical is available for.
Intrinsic value
2%
Share price is $15.15 vs Future cash flow value of $15.45
Current Discount Checks
For Santen Pharmaceutical to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Santen Pharmaceutical's share price is below the future cash flow value, but not at a moderate discount (< 20%).
  • Santen Pharmaceutical's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Santen Pharmaceutical's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Santen Pharmaceutical's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
OTCPK:SNPH.F PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in JPY ¥78.67
TSE:4536 Share Price ** TSE (2019-05-02) in JPY ¥1710
United States of America Pharmaceuticals Industry PE Ratio Median Figure of 29 Publicly-Listed Pharmaceuticals Companies 17.89x
United States of America Market PE Ratio Median Figure of 3,095 Publicly-Listed Companies 17.88x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Santen Pharmaceutical.

OTCPK:SNPH.F PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= TSE:4536 Share Price ÷ EPS (both in JPY)

= 1710 ÷ 78.67

21.74x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Santen Pharmaceutical is overvalued based on earnings compared to the US Pharmaceuticals industry average.
  • Santen Pharmaceutical is overvalued based on earnings compared to the United States of America market.
Price based on expected Growth
Does Santen Pharmaceutical's expected growth come at a high price?
Raw Data
OTCPK:SNPH.F PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 21.74x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 10 Analysts
5%per year
United States of America Pharmaceuticals Industry PEG Ratio Median Figure of 21 Publicly-Listed Pharmaceuticals Companies 1.67x
United States of America Market PEG Ratio Median Figure of 2,134 Publicly-Listed Companies 1.54x

*Line of best fit is calculated by linear regression .

OTCPK:SNPH.F PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 21.74x ÷ 5%

4.35x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Santen Pharmaceutical is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Santen Pharmaceutical's assets?
Raw Data
OTCPK:SNPH.F PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in JPY ¥728.86
TSE:4536 Share Price * TSE (2019-05-02) in JPY ¥1710
United States of America Pharmaceuticals Industry PB Ratio Median Figure of 183 Publicly-Listed Pharmaceuticals Companies 3.33x
United States of America Market PB Ratio Median Figure of 5,255 Publicly-Listed Companies 1.8x
OTCPK:SNPH.F PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= TSE:4536 Share Price ÷ Book Value per Share (both in JPY)

= 1710 ÷ 728.86

2.35x

* Primary Listing of Santen Pharmaceutical.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Santen Pharmaceutical is good value based on assets compared to the US Pharmaceuticals industry average.
X
Value checks
We assess Santen Pharmaceutical's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Santen Pharmaceutical has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Santen Pharmaceutical expected to perform in the next 1 to 3 years based on estimates from 10 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Santen Pharmaceutical expected to grow at an attractive rate?
  • Santen Pharmaceutical's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Santen Pharmaceutical's earnings growth is positive but not above the United States of America market average.
  • Santen Pharmaceutical's revenue growth is positive but not above the United States of America market average.
Annual Growth Rates Comparison
Raw Data
OTCPK:SNPH.F Future Growth Rates Data Sources
Data Point Source Value (per year)
OTCPK:SNPH.F Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 10 Analysts 5%
OTCPK:SNPH.F Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 10 Analysts 3.1%
United States of America Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 15%
United States of America Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 5.4%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
OTCPK:SNPH.F Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 10 Analyst Estimates (S&P Global) See Below
All numbers in JPY Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
OTCPK:SNPH.F Future Estimates Data
Date (Data in JPY Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-03-31 270,238 53,257 35,825 4
2023-03-31 270,020 53,127 37,000 5
2022-03-31 266,444 44,884 34,517 9
2021-03-31 256,742 42,666 32,634 10
2020-03-31 248,217 37,410 23,803 10
OTCPK:SNPH.F Past Financials Data
Date (Data in JPY Millions) Revenue Cash Flow Net Income *
2019-03-31 234,026 32,894 31,954
2018-12-31 229,560 36,492 31,291
2018-09-30 228,512 38,360 34,370
2018-06-30 225,477 34,561 33,083
2018-03-31 224,942 42,843 35,247
2017-12-31 217,021 39,581 30,580
2017-09-30 212,041 37,624 25,717
2017-06-30 205,038 30,180 24,756
2017-03-31 199,096 10,843 23,061
2016-12-31 196,754 4,869 23,299
2016-09-30 195,247 5,091 22,317
2016-06-30 197,322 8,601 53,155

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Santen Pharmaceutical's earnings are expected to grow by 5% yearly, however this is not considered high growth (20% yearly).
  • Santen Pharmaceutical's revenue is expected to grow by 3.1% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
OTCPK:SNPH.F Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 10 Analyst Estimates (S&P Global) See Below

All data from Santen Pharmaceutical Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:SNPH.F Future Estimates Data
Date (Data in JPY Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-03-31 89.93 114.10 63.39 4.00
2023-03-31 87.33 103.80 67.65 4.00
2022-03-31 86.06 107.70 75.67 9.00
2021-03-31 81.03 102.00 73.20 11.00
2020-03-31 59.10 61.60 55.62 9.00
OTCPK:SNPH.F Past Financials Data
Date (Data in JPY Millions) EPS *
2019-03-31 78.67
2018-12-31 76.90
2018-09-30 84.50
2018-06-30 81.37
2018-03-31 86.73
2017-12-31 75.27
2017-09-30 63.27
2017-06-30 60.63
2017-03-31 56.20
2016-12-31 56.51
2016-09-30 53.91
2016-06-30 128.40

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Santen Pharmaceutical is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Santen Pharmaceutical's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Santen Pharmaceutical has a total score of 1/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Santen Pharmaceutical performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Santen Pharmaceutical's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Santen Pharmaceutical's year on year earnings growth rate has been positive over the past 5 years.
  • Santen Pharmaceutical's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • Santen Pharmaceutical's 1-year earnings growth is negative, it can't be compared to the US Pharmaceuticals industry average.
Earnings and Revenue History
Santen Pharmaceutical's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Santen Pharmaceutical Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:SNPH.F Past Revenue, Cash Flow and Net Income Data
Date (Data in JPY Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 234,026.00 31,954.00 71,273.00 23,759.00
2018-12-31 229,560.00 31,291.00 101,646.00 -804.00
2018-09-30 228,512.00 34,370.00 101,724.00 -778.00
2018-06-30 225,477.00 33,083.00 101,043.00 6.00
2018-03-31 224,942.00 35,247.00 99,926.00
2017-12-31 217,021.00 30,580.00 65,855.00 24,751.00
2017-09-30 212,041.00 25,717.00 63,872.00 24,224.00
2017-06-30 205,038.00 24,756.00 61,890.00 23,241.00
2017-03-31 199,096.00 23,061.00 60,934.00 22,786.00
2016-12-31 196,754.00 23,299.00 59,898.00 21,636.00
2016-09-30 195,247.00 22,317.00 59,532.00 21,051.00
2016-06-30 197,322.00 53,155.00 59,169.00 20,561.00
2016-03-31 195,291.00 53,373.00 58,382.00 19,990.00
2015-12-31 194,193.00 57,729.00 40,107.00 31,761.00
2015-09-30 187,779.00 58,590.00 43,524.00 26,720.00
2015-06-30 176,124.00 27,842.00 46,681.00 22,064.00
2015-03-31 161,831.00 24,032.00 48,074.00 17,477.00
2014-12-31 156,559.00 17,923.00 52,398.00 19,040.00
2014-09-30 151,325.00 17,214.00 48,597.00 19,040.00
2014-06-30 148,031.00 15,278.00 45,812.00 19,040.00
2014-03-31 148,663.00 17,109.00 44,104.00 19,040.00
2013-12-31 139,587.00 17,760.00 40,808.00 16,719.00
2013-09-30 131,614.00 16,536.00 38,997.00 16,719.00
2013-06-30 125,422.00 17,805.00 36,775.00 16,719.00
2013-03-31 119,066.00 16,520.00 36,164.00 16,719.00
2012-12-31 116,403.00 16,530.00 35,902.00 17,225.00
2012-09-30 114,342.00 16,233.00 35,434.00 17,225.00
2012-06-30 114,524.00 15,911.00 36,025.00 17,225.00

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Santen Pharmaceutical has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Santen Pharmaceutical used its assets less efficiently than the US Pharmaceuticals industry average last year based on Return on Assets.
  • Santen Pharmaceutical has improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Santen Pharmaceutical's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Santen Pharmaceutical has a total score of 2/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Santen Pharmaceutical's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Santen Pharmaceutical's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Santen Pharmaceutical is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Santen Pharmaceutical's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Santen Pharmaceutical's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Santen Pharmaceutical has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Santen Pharmaceutical Company Filings, last reported 2 months ago.

OTCPK:SNPH.F Past Debt and Equity Data
Date (Data in JPY Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 292,572.00 0.00 70,796.00
2018-12-31 298,769.00 0.00 75,394.00
2018-09-30 304,597.00 0.00 75,237.00
2018-06-30 289,287.00 0.00 57,483.00
2018-03-31 287,557.00 7,598.00 69,283.00
2017-12-31 281,223.00 0.00 60,048.00
2017-09-30 271,799.00 0.00 61,846.00
2017-06-30 260,636.00 0.00 48,952.00
2017-03-31 253,884.00 16,929.00 53,297.00
2016-12-31 253,966.00 0.00 48,100.00
2016-09-30 255,065.00 0.00 58,343.00
2016-06-30 256,254.00 0.00 74,516.00
2016-03-31 260,009.00 22,438.00 99,798.00
2015-12-31 258,716.00 0.00 104,062.00
2015-09-30 250,899.00 0.00 108,011.00
2015-06-30 216,498.00 0.00 56,161.00
2015-03-31 211,779.00 37,071.00 65,923.00
2014-12-31 195,514.00 40,021.00 59,504.00
2014-09-30 188,201.00 35,000.00 53,575.00
2014-06-30 180,767.00 35,000.00 101,322.00
2014-03-31 181,208.00 0.00 76,620.00
2013-12-31 178,416.00 0.00 67,035.00
2013-09-30 171,526.00 0.00 65,096.00
2013-06-30 168,499.00 0.00 56,871.00
2013-03-31 165,132.00 0.00 61,891.00
2012-12-31 156,905.00 0.00 60,123.00
2012-09-30 154,521.00 0.00 62,000.00
2012-06-30 164,682.00 0.00 66,763.00
  • Santen Pharmaceutical has no debt.
  • Santen Pharmaceutical has no debt compared to 5 years ago when it was 0.2%.
  • Santen Pharmaceutical has no debt, it does not need to be covered by operating cash flow.
  • Santen Pharmaceutical has no debt, therefore coverage of interest payments is not a concern.
X
Financial health checks
We assess Santen Pharmaceutical's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Santen Pharmaceutical has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Santen Pharmaceutical's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
1.52%
Current annual income from Santen Pharmaceutical dividends. Estimated to be 1.64% next year.
If you bought $2,000 of Santen Pharmaceutical shares you are expected to receive $30 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Santen Pharmaceutical's pays a higher dividend yield than the bottom 25% of dividend payers in United States of America (1.44%).
  • Santen Pharmaceutical's dividend is below the markets top 25% of dividend payers in United States of America (3.73%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
OTCPK:SNPH.F Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 10 Analyst Estimates (S&P Global) See Below
United States of America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 2.7%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2012 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

OTCPK:SNPH.F Future Dividends Estimate Data
Date (Data in ¥) Dividend per Share (annual) Avg. No. Analysts
2024-03-31 29.00 4.00
2023-03-31 29.80 5.00
2022-03-31 28.33 9.00
2021-03-31 28.00 11.00
2020-03-31 26.22 9.00
OTCPK:SNPH.F Past Annualized Dividends Data
Date (Data in ¥) Dividend per share (annual) Avg. Yield (%)
2019-05-09 26.000 1.589
2019-02-08 26.000 1.575
2019-02-05 26.000 1.730
2018-11-09 26.000 1.544
2018-11-07 26.000 1.454
2018-06-26 26.000 1.477
2018-05-09 26.000 1.357
2018-02-09 26.000 1.496
2018-02-06 26.000 1.558
2017-11-07 26.000 1.451
2017-11-01 26.000 1.470
2017-06-23 26.000 1.541
2017-05-10 26.000 1.707
2017-02-10 26.000 1.621
2017-02-07 26.000 1.656
2016-11-04 26.000 1.832
2016-11-02 26.000 1.779
2016-06-24 26.000 1.724
2016-05-11 26.000 1.630
2016-02-05 24.000 1.433
2016-02-02 24.000 1.225
2015-11-06 24.000 1.248
2015-11-04 24.000 1.391
2015-08-04 24.000 1.373
2015-05-12 24.000 1.363
2015-02-06 20.000 1.230
2015-02-03 20.000 1.361
2014-11-07 20.000 1.489
2014-11-05 20.000 1.500
2014-06-25 20.000 1.659
2014-05-13 20.000 1.820
2014-02-07 20.000 2.179
2014-02-04 20.000 2.379
2013-11-06 20.000 2.098
2013-06-25 20.000 2.138
2013-05-08 20.000 2.273
2013-02-08 20.000 2.294
2013-02-05 20.000 2.687
2012-11-09 20.000 2.857
2012-11-01 20.000 2.917
2012-08-01 20.000 2.895
2012-06-20 20.000 3.076
2012-05-08 20.000 3.426
2012-02-10 20.000 3.004
2012-02-07 20.000 3.228
2011-11-04 20.000 3.307
2011-11-01 20.000 3.215
2011-08-02 20.000 3.210
2011-06-22 20.000 3.131
2011-05-10 20.000 3.139
2011-02-08 16.000 2.558
2010-11-05 16.000 2.771
2010-11-02 16.000 2.876
2010-06-23 16.000 2.676
2010-05-11 16.000 2.657
2010-02-09 16.000 2.773
2010-02-02 16.000 2.824
2009-11-10 16.000 2.782

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Dividends per share have been stable in the past 10 years.
  • Dividends per share have increased over the past 10 years.
Current Payout to shareholders
What portion of Santen Pharmaceutical's earnings are paid to the shareholders as a dividend.
  • Dividends paid are well covered by earnings (3x coverage).
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Santen Pharmaceutical's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Santen Pharmaceutical afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Santen Pharmaceutical has a total score of 4/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Santen Pharmaceutical's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Akira Kurokawa
COMPENSATION ¥108,000,000
TENURE AS CEO 11.4 years
CEO Bio

Mr. Akira Kurokawa has been the Chief Executive Officer and Chairman of Santen Pharmaceutical Co. Ltd. since 2008 and April 01, 2018 respectively and served as its President since 2006 until April 01, 2018. Mr. Kurokawa served as the Chief Operating Officer, Senior Corporate Officer and Head of Sales & Marketing Division, Prescription Pharmaceuticals at Santen Pharmaceutical Co. Ltd. since 2006, 2004 and 1997 respectively. He joined Santen Pharmaceutical Co. Ltd. in 1977. He served as the Chief Executive Officer and President at Santen Incorporated. He has been a Representative Director of Santen Pharmaceutical Co. Ltd. since 1997.

CEO Compensation
  • Akira's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Akira's remuneration is lower than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure of the Santen Pharmaceutical management team in years:

2.2
Average Tenure
  • The tenure for the Santen Pharmaceutical management team is about average.
Management Team

Akira Kurokawa

TITLE
Chairman & CEO
COMPENSATION
¥108M
TENURE
11.4 yrs

Shigeo Taniuchi

TITLE
President
AGE
45
TENURE
1.2 yrs

Kazuo Koshiji

TITLE
Senior Corp. Officer of Corporate Administration

Naveed Shams

TITLE
Senior Corporate Officer
AGE
61

Noriaki Yamamoto

TITLE
Corporate Officer
TENURE
5.2 yrs

Christopher Hohman

TITLE
General Manager Corporate Communications Group

Satoshi Suzuki

TITLE
Senior Corporate Officer
TENURE
2.2 yrs

Takahiro Morita

TITLE
Corporate Officer & Head of Sales Department
TENURE
0.2 yrs

Miki Fujima

TITLE
Corporate Officer & Head of Human Resources Division
TENURE
0.2 yrs

Kenji Morishima

TITLE
Corporate Officer and Head of Pharmaceutics & Pharmacology Department
TENURE
5.2 yrs
Board of Directors Tenure

Average tenure and age of the Santen Pharmaceutical board of directors in years:

2
Average Tenure
57
Average Age
  • The average tenure for the Santen Pharmaceutical board of directors is less than 3 years, this suggests a new board.
Board of Directors

Akira Kurokawa

TITLE
Chairman & CEO
COMPENSATION
¥108M
TENURE
1.2 yrs

Shigeo Taniuchi

TITLE
President
AGE
45
TENURE
1.9 yrs

Takeshi Ito

TITLE
Head of Japan Sales & Mktg Division
TENURE
1.9 yrs

Kanoko Oishi

TITLE
Outside Director
AGE
57
TENURE
4 yrs

Yutaro Shintaku

TITLE
Outside Director
TENURE
2 yrs

Kunihito Minakawa

TITLE
Outside Director
AGE
64
TENURE
1 yrs

Yutaka Mizuno

TITLE
Outside Corporate Auditor
TENURE
8.4 yrs

Seiichiro Adachi

TITLE
Outside Corporate Auditor
TENURE
4.4 yrs

Masashi Murata

TITLE
Standing Corporate Auditor
TENURE
3 yrs

Yasuyuki Miyasaka

TITLE
Outside Corporate Auditor
TENURE
1 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess Santen Pharmaceutical's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Santen Pharmaceutical has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Santen Pharmaceutical Co., Ltd. researches and develops, produces, and markets pharmaceuticals and medical devices in Japan and internationally. It offers prescription pharmaceutical products for glaucoma and ocular hypertension, dry eyes, allergic conjunctivitis, severe keratitis with dry eyes, vernal keratoconjunctivitis, uveitis, wet age-related macular degeneration, and myopia; and over-the-counter pharmaceutical products. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.

Details
Name: Santen Pharmaceutical Co., Ltd.
SNPH.F
Exchange: OTCPK
Founded: 1890
¥6,362,483,807
399,162,142
Website: http://www.santen.com
Address: Santen Pharmaceutical Co., Ltd.
Grand Front Osaka Tower A,
4-20 Ofuka-cho,
Osaka,
530-8552,
Japan
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
TSE 4536 Common Stock The Tokyo Stock Exchange JP JPY 01. Jan 1992
OTCPK SNPH.F Common Stock Pink Sheets LLC US USD 01. Jan 1992
DB SZD Common Stock Deutsche Boerse AG DE EUR 01. Jan 1992
OTCPK SNPH.Y ADR Pink Sheets LLC US USD 17. Sep 2010
Number of employees
Current staff
Staff numbers
3,805
Santen Pharmaceutical employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/06/24 23:52
End of day share price update: 2019/05/02 00:00
Last estimates confirmation: 2019/06/23
Last earnings filing: 2019/05/09
Last earnings reported: 2019/03/31
Last annual earnings reported: 2019/03/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.